Skip to main content

Table 1 Characteristics of the total sample of self-harming adolescents with depression, and a comparison between the adolescents with full-syndrome Borderline Personality Disorder (BPD) and with sub-threshold BPD at baseline and at trial completion

From: The impact of borderline personality disorder and sub-threshold borderline personality disorder on the course of self-reported and clinician-rated depression in self-harming adolescents

  Total Full-syndrome BPD Sub-threshold BPD P
  n (%)   n (%)   n (%)   
Girls 34 (87.2)   10 (100)   24 (82.8)   .30
Receiving DBT-A treatment 21 (53.8)   5 (50.0)   16 (55.2)   1.0
History of psychiatric treatment 22 (57.9)   7 (70.0)   15 (53.6)   .47
5 BPD criteria or more 14 (35.9)   10 (100)   4 (13.8)   <.001
MDD 15 (38.5)   4 (40.0)   11 (37.9)   1.0
Dysthymia 6 (15.4)   1 (10.0)   5 (17.2)   1.0
Depression NOS 18 (46.2)   5 (50.0)   13 (44.8)   1.0
Any anxiety disorder 19 (48.7)   3 (30.0)   16 (55.2)   .27
  Mean (SD) n1 + n2 Mean (SD) n1 Mean (SD) n2  
Age, years 15.8 (1.7) 39 16.9 (1.7) 10 15.5 (1.5) 29 .02
SMFQ
 Baseline 16.3 (5.3) 39 19.4 (4.7)a 10 15.2 (5.1)c 29 .03
 -DBT   21 17.2 (3.0) 5 14.0 (5.4) 16  
 -EUC   18 21.6 (5.4) 5 16.8 (4.5) 13  
 Trial completion 12.3 (6.2) 39 16.5 (5.7)a 10 10.8 (5.8)c 29 .01
 -DBT   21 15.2 (5.7) 5 9.1 (4.6) 16  
 -EUC   18 17.8 (6.1) 5 12.9 (6.5) 13  
MADRS
 Baseline 22.1 (6.2) 39 22.2 (5.7)a 10 22.0 (6.4)c 29 .94
 -DBT   21 26.2 (2.6) 5 21.6 (7.2) 16  
 -EUC   18 18.2 (5.1) 5 22.6 (5.4) 13  
 Trial completion 15.1 (8.1) 39 20.5 (6.3)a 10 13.3 (7.8)c 29 .01
 -DBT   21 19.6 (8.6) 5 10.3 (7.2) 16  
 -EUC   18 21.4 (3.8) 5 16.8 (7.2) 13  
C-GAS
 Baseline 53.3 (7.0) 39 52.1 (6.9)b 10 53.7 (7.1)c 29 .56
 -DBT   21 52.6 (7.2) 5 54.0 (8.4) 16  
 -EUC   18 51.7 (7.4) 5 53.2 (5.6) 13  
 Trial completion 64.1 (11.5) 39 56.8 (6.6)b 10 66.6 (11.9)c 29 .003
 -DBT   21 59.4 (6.6) 5 69.6 (9.2) 16  
 -EUC   18 54.2 (6.1) 5 62.9 (14.0) 13  
SIQ-jr
 Baseline 39.9 (21.5) 39 53.5 (23.1)b 10 35.2 (19.1)c 29 .02
 -DBT   21 45.3 (17.1) 5 30.3 (14.6) 16  
 -EUC   18 61.8 (27.1) 5 41.2 (22.7) 13  
 Trial completion 27.4 (20.0) 39 34.1 (21.3)b 10 25.1 (19.4)c 29 .23
 -DBT   21 26.5 (6.3) 5 16.4 (11.6) 16  
 -EUC   18 41.7 (28.9) 5 35.8 (21.9) 13  
Lifetime episodes of self-harm (n) d 49.0, 98.5 39 89.0, 239.5 10 44.0, 76.3 29 .20
n. of Axis 1 Disordersd 2.0, 2.0 39 2.0, 2.0 10 2.0, 2.0 29 .89
n. of BPD-criteriad 4.0, 2.0 39 6.0, 2.0 10 3.0, 2.0. 29 <.001
  1. a A paired samples test showed a non-significant reduction in SMFQ (p = .16) and MADRS (p = .55) from baseline to trial completion
  2. b A paired samples test showed a significant reduction in SIQ-jr (p = .01) and CGAS (p = .04) from baseline to trial completion
  3. c A paired samples test showed a significant reduction in SMFQ (p = .001), MADRS (p < .001), CGAS (p < .001) and SIQ-jr (p = .04) from baseline to trial completion
  4. d median, interquartile range